Rule 3.8A

Appendix 3E

Daily share buy-back notice (*except* minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public. Introduced 1/9/99. Origin: rule 3.6, Appendix 7C. Amended 30/9/2001.

Name of entity	ABN
BIOTECH CAPITAL LIMITED	45 091 979 172

We (the entity) give ASX the following information.

Information about buy-back

1 Type of buy-back

On-Market

2 Date Appendix 3C was given to ASX

24 November 2008

Total of all shares bought back, or in relation to which acceptances have been received, before, and on, previous day

		Before previous day	Previous day (close 29/5/09)
3	Number of shares bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received	1,672,850	70,000
4	Total consideration paid or payable for the shares	\$275,901.72	\$13,300.00

⁺ See chapter 19 for defined terms.

		Before previous day	Previous day (close 29/5/09)
5	If buy-back is an on-market buy- back	highest price paid: \$0.19 lowest price paid: \$0.19	highest price paid: \$0.19 lowest price paid: \$0.19 highest price allowed under rule 7.33: \$0.199

Participation by directors

6 Deleted 30/9/2001.

Nil			

How many shares may still be bought back?

7 If the company has disclosed an 2 intention to buy back a maximum number of shares - the remaining number of shares to be bought back

2,459,125

Compliance statement

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here:	Baden Bowen (Company Secretary)	Date: 29/5/09
Print name:	Baden Bowen	

⁺ See chapter 19 for defined terms.